Nabil Lally

  In an industry where innovation alone is not enough, Nabil Lally brings a rare and essential blend of scientific expertise and strategic thinking to the world of drug development. As Senior Director of Business Development at Quotient Sciences , Nabil has built a reputation for delivering real results by combining deep technical knowledge with an instinct for collaboration and forward-thinking execution. At the core of Nabil’s work is a commitment to accelerating the development of new therapies without compromising quality. He plays a leading role in promoting Translational Pharmaceutics® , Quotient Sciences’ unique integrated platform that unites formulation development, GMP manufacturing, and clinical testing within a single streamlined process. This approach enables companies to gather real-time clinical data and make adaptive decisions faster than traditional models allow, shaving up to 12 months off development timelines. But what makes Nabil a standout leader is not ju...

  The American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2025 Annual Meeting  in Washington, D.C. marked another significant milestone in the evolution of translational medicine. Gathering researchers, clinicians, and leaders from across the globe, ASCPT 2025 served as a dynamic forum for scientific exchange, collaboration, and insights into the future of drug development. Representing Quotient Sciences , Nabil Lally , Senior Director of Business Development, and Dr . Andreas Reichl , Senior Drug Development Consultant, brought cutting-edge perspectives to this pivotal event.   Their participation underscored Quotient Sciences’ commitment to transforming the traditional drug development pathway through its integrated Translational Pharmaceutics    platform and consultative, science-led approach to clinical pharmacology. Setting the Stage: Why ASCPT Matters ASCPT is widely recognized as the premier scientific conference in clinical pharmacology, ...